2009
DOI: 10.1002/qsar.200810164
|View full text |Cite
|
Sign up to set email alerts
|

An Influence of the Aromatic Side Chains Conformations in Positions 2 and 3 of Vasopressin Analogs on Interactions with Vasopressin and Oxytocin Receptors

Abstract: In this work, the receptor-bound conformation of nine vasopressin (CYFQNCPRG-NH 2 , AVP) analogs substituted in positions 2 or 3 with 2-aminoindane-2-carboxylic acid have been investigated using molecular modeling methods. The synthesis and functional assays of the analogs have been recently described. For comparison, the molecular dynamics of the selected analogs has been conducted. We have observed the relationship between the value of valence angle between the aromatic rings in positions 2 and 3 and the bio… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2012
2012
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 66 publications
0
1
0
Order By: Relevance
“…Here, we focus on the properties of the most widely used peptides requested from the Manning laboratory or purchased from suppliers, together with some recently reported potential clinically useful peptides from the Ferring Laboratory ( 38 , 39 ). Space considerations preclude our being able to present or to discuss recent synthetic studies carried out in other laboratories ( 40–43 ). We also update the current status of the pre-clinical and clinical development of nonpeptide AVP and OT antagonists and of the pre-clinical development of nonpeptide OT agonists ( 44 ).…”
Section: Scope Of the Present Reviewmentioning
confidence: 99%
“…Here, we focus on the properties of the most widely used peptides requested from the Manning laboratory or purchased from suppliers, together with some recently reported potential clinically useful peptides from the Ferring Laboratory ( 38 , 39 ). Space considerations preclude our being able to present or to discuss recent synthetic studies carried out in other laboratories ( 40–43 ). We also update the current status of the pre-clinical and clinical development of nonpeptide AVP and OT antagonists and of the pre-clinical development of nonpeptide OT agonists ( 44 ).…”
Section: Scope Of the Present Reviewmentioning
confidence: 99%